Education
About Us
Working with TipRanks
Follow Us
Torrent Pharmaceuticals Ltd (IN:TORNTPHARM)
:TORNTPHARM
TORNTPHARM Stock Chart & Stats
₹3578.85
-₹79.35(-2.33%)
At close: 4:00 PM EST
₹3578.85
-₹79.35(-2.33%)
Day’s Range― - ―
52-Week Range₹2,891.45 - ₹4,322.80
Previous CloseN/A
Volume167.59K
Average Volume (3M)7.49K
Market Cap
₹1.44T
Enterprise Value₹1.45T
Total Cash (Recent Filing)₹6.88B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)63.4
Beta0.61
Next Earnings
May 21, 2026EPS Estimate
24.3Next Dividend Ex-DateN/A
Dividend Yield0.84%
Share Statistics
EPS (TTM)19.00
Shares Outstanding338,431,850
10 Day Avg. Volume2,743
30 Day Avg. Volume7,494
Financial Highlights & Ratios
PEG Ratio3.66
Price to Book (P/B)14.19
Price to Sales (P/S)9.36
P/FCF Ratio54.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained, high free cash flow growth and FCF roughly equaling reported earnings indicate robust cash conversion. This durable cash generation supports capex, regulatory investments, deleveraging, and optionality for M&A or shareholder returns over the next several quarters.
Robust Operating MarginsElevated gross and EBIT margins alongside recurring revenue growth reflect scalable manufacturing and effective cost control. Higher structural margins provide resilience against pricing pressure in generics and fund reinvestment in brands and geographic expansion over a multi-quarter horizon.
Improved Balance Sheet And LeverageLower leverage and a strong equity base enhance financial flexibility for investments and cyclical shocks. A healthy balance sheet supports sustained funding of commercial expansion and R&D, and reduces refinancing risk across the next several quarters.
Bears Say
Net Profit Margin HeadroomDespite strong gross and EBIT margins, net margin lags, implying SG&A, other costs or tax inefficiencies. Persistent pressure here would constrain retained earnings and reinvestment capacity; management must improve expense control or asset turnover to lift durable profitability.
Exposure To Generic Pricing PressureStructural competitive dynamics in branded generics and regulated tenders can compress prices and margins over time. Torrent's reliance on these markets leaves revenues and profitability exposed unless it sustains brand differentiation, specialty franchises, or geographic diversification.
Regulatory And Market Access RiskGrowth in regulated international markets hinges on timely approvals and manufacturing compliance. Inspection failures or approval delays can disrupt supply and market entry, creating a multi-quarter drag on international sales and the company’s expansion trajectory.
Torrent Pharmaceuticals Ltd News
TORNTPHARM FAQ
What was Torrent Pharmaceuticals Ltd’s price range in the past 12 months?
Torrent Pharmaceuticals Ltd lowest stock price was ₹2891.45 and its highest was ₹4322.80 in the past 12 months.
What is Torrent Pharmaceuticals Ltd’s market cap?
Torrent Pharmaceuticals Ltd’s market cap is ₹1.44T.
When is Torrent Pharmaceuticals Ltd’s upcoming earnings report date?
Torrent Pharmaceuticals Ltd’s upcoming earnings report date is May 21, 2026 which is in 91 days.
How were Torrent Pharmaceuticals Ltd’s earnings last quarter?
Torrent Pharmaceuticals Ltd released its earnings results on Feb 13, 2026. The company reported ₹19 earnings per share for the quarter, beating the consensus estimate of ₹18.196 by ₹0.804.
Is Torrent Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Torrent Pharmaceuticals Ltd’s price is currently Overvalued.
Does Torrent Pharmaceuticals Ltd pay dividends?
Torrent Pharmaceuticals Ltd pays a Notavailable dividend of ₹6 which represents an annual dividend yield of 0.84%. See more information on Torrent Pharmaceuticals Ltd dividends here
What is Torrent Pharmaceuticals Ltd’s EPS estimate?
Torrent Pharmaceuticals Ltd’s EPS estimate is 24.3.
How many shares outstanding does Torrent Pharmaceuticals Ltd have?
Torrent Pharmaceuticals Ltd has 338,431,850 shares outstanding.
What happened to Torrent Pharmaceuticals Ltd’s price movement after its last earnings report?
Torrent Pharmaceuticals Ltd reported an EPS of ₹19 in its last earnings report, beating expectations of ₹18.196. Following the earnings report the stock price went down -0.185%.
Which hedge fund is a major shareholder of Torrent Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in IN:TORNTPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. It offers products in various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, women healthcare, diabetology, pain management, gynecology, oncology, and anti-infective, as well as provides vitamins, minerals, and nutrients. The company also provides contract manufacturing services. It has licensing collaborations of Baricitinib, Molnupiravir, and Paxlovid for its Covid portfolio. Torrent Pharmaceuticals Limited was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
Technical Analysis
Cipla Ltd
―
Divi's Laboratories Limited
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Zydus Lifesciences Limited
―